Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD + Blinatumomab +/- Inotuzumab Ozogamicin in Frontline B-Cell ALL
NCT02877303Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2016
- Primary completion
- Nov 2026
- Modality
- scFv Fragments, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab, inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL), B-cell lymphoblastic lymphoma (B-LBL), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2016; status: recruiting.
02
Drugs
blinatumomabinotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NCT02877303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02877303.